Risk charts to guide targeted HIV-1 viral load monitoring of ART: development and validation in patients from resource-limited settings. by Koller, Manuel et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print
DOI: 10.1097/QAI.0000000000000748
1 
 
 
Risk charts to guide targeted HIV-1 viral load monitoring of ART: 
development and validation in patients from resource-limited settings 
 
 
Manuel Koller, PhD
a
, Geoffrey Fatti, MD
b
, Benjamin H Chi, MD
c
, Olivia Keiser, PhD
a
, Christopher J 
Hoffmann, MD
d
, Robin Wood, MD
e
, Hans Prozesky, MD
f
, Kathryn Stinson, MD
g
, Janet Giddy, MD
h
, 
Portia Mutevedzi, PhD
i
, Matthew Fox, PhD
j,k
, Matthew Law, PhD
l
, Andrew Boulle, MD, PhD
m
,  
and Matthias Egger, MD
a,m 
 
on behalf of the International epidemiological Databases to Evaluate AIDS in Southern Africa (IeDEA-
SA) and the TREAT Asia HIV Observational Database (TAHOD) 
 
a) Institute of Social and Preventive Medicine, University of Bern, Switzerland 
b) Kheth’Impilo, Cape Town, South Africa 
c) Centre for Infectious Disease Research in Zambia, Lusaka, Zambia 
d) Aurum Institute for Health Research, Johannesburg, South Africa 
e) Gugulethu ART Programme and Desmond Tutu HIV Centre, University of Cape Town, South Africa 
f) Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg 
Academic Hospital, Cape Town, South Africa  
g) Médecins Sans Frontières, Khayelitsha, Cape Town, South Africa 
h) Sinikithemba Clinic, McCord Hospital, Durban, South Africa 
i) Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South 
Africa 
j) Health Economics and Epidemiology Research Office, University of the Witwatersrand, 
Johannesburg, South Africa 
k) Center for Global Health & Development and Department of Epidemiology, Boston University, 
Boston, USA 
l) Biostatistics and Databases Program, The Kirby Institute, Faculty of Medicine, The University of 
New South Wales, Sydney, Australia 
m) Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family 
Medicine, University of Cape Town, South Africa 
 
Correspondence to: 
Professor Matthias Egger 
Institute of Social and Preventive Medicine (ISPM) 
University of Bern 
Finkenhubelweg 11, CH-3012 Bern, Switzerland 
egger@ispm.unibe.ch 
 
Abstract 242 words, main text 3306 words, 2 tables, 3 figures, 39 references, supplementary web 
appendix (with 6 tables, 3 figures, and a technical appendix) 
AC
CE
PT
ED
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
71
00
6 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
2 
 
 
Competing Interests: The authors have declared that no competing interests exist. 
Sources of Funding: IeDEA Southern Africa and TAHOD are supported by the National Institutes of 
Health (NIH): National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child 
Health and Human Development (NICHD), the Office of the Director (OD), and the National Cancer 
Institute (NCI), as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA, grants 
U01AI069924 and U01AI069907). TAHOD is part of the Asia Pacific HIV Observational Database and is 
an initiative of TREAT Asia, a program of amfAR and The Foundation for AIDS Research. TAHOD is also 
supported by the Dutch Ministry of Foreign Affairs through a partnership with Stichting Aids Fonds. 
The funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. M Fox was supported by Cooperative Agreement AID 674-A-12-00029 
from the United States Agency for International Development (USAID). OK was supported by a 
PROSPER Ambizione fellowship of the Swiss National Science Foundation. 
 
Keywords: Antiretroviral therapy; monitoring; CD4 cell counts; risk charts; tripartite decision 
rules; Sub-Saharan Africa 
 
AC
CE
PT
ED
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
3 
 
 
Abstract 
 
 
Background: HIV-1 RNA viral load (VL) testing is recommended to monitor antiretroviral therapy 
(ART) but not available in many resource-limited settings. We developed and validated CD4-based 
risk charts to guide targeted VL testing. 
Methods:  We modeled the probability of virologic failure up to 5 years of ART based on current and 
baseline CD4 counts, developed decision rules for targeted VL testing of 10%, 20% or 40% of patients 
in seven cohorts of patients starting ART in South Africa, and plotted cut-offs for VL testing on colour-
coded risk charts. We assessed the accuracy of risk chart-guided VL testing to detect virologic failure 
in validation cohorts from South Africa, Zambia and the Asia-Pacific. 
Findings: 31,450 adult patients were included in the derivation and 25,294 patients in the validation 
cohorts. Positive predictive values increased with the percentage of patients tested: from 79% (10% 
tested) to 98% (40% tested) in the South African, from 64% to 93% in the Zambian and from 73% to 
96% in the Asia-Pacific cohorts. Corresponding increases in sensitivity were from 35% to 68% in South 
Africa, from 55% to 82% in Zambia and from 37% to 71% in Asia-Pacific. The area under the receiver-
operating curve increased from 0.75 to 0.91 in South Africa, from 0.76 to 0.91 in Zambia and from 
0.77 to 0.92 in Asia Pacific.  
Interpretation:  CD4-based risk charts with optimal cut-offs for targeted VL testing may be useful to 
monitor ART in settings where VL capacity is limited.  
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Introduction 
 
Since 2002 the number of HIV-positive people receiving antiretroviral therapy (ART) in low- and 
middle-income countries has increased dramatically, from 300,000 in 2002 to 10 million by the end 
of 2012, representing two thirds of the United Nations target of 15 million people on ART by 2015.
1
 
The massive scale-up of ART also increased the number of patients experiencing treatment failure, 
the need for more expensive second-line regimens, and levels of viral resistance.
2,3
  
Clinical and laboratory monitoring of patients on ART aims to maximize the durability of first-line 
regimens. In high-income countries plasma HIV 1-RNA viral load (VL) and CD4 positive T cell count 
(CD4 count) are regularly measured and tests are done when drug resistance is suspected.
4
 In 
resource-limited settings monitoring of ART is, however, still generally based on CD4 counts and 
signs and symptoms. The accuracy of the criteria proposed by the World Health Organization (WHO)
5
 
to detect virologic failure based on CD4 count and clinical criteria is poor: the positive predictive 
value (PPV) and sensitivity are below 50%.
6,7
 Patients with suppressed viral replication may thus 
unnecessarily be switched to second-line ART, and patients who fail therapy will switch late, or not 
switch at all.
8
 The 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating 
and preventing HIV infection and the March 2014 supplement recommend routine VL monitoring, 
but recognize that scaling up VL testing in resource limited settings will be challenging.
9,10
  
In settings where VL is not monitored routinely the first priority should be to confirm virologic failure 
in patients in whom treatment failure is suspected, based on CD4 count and clinical monitoring.
10
 
Targeted VL testing of selected patients based on CD4 count and other criteria is promising in this 
situation: only relatively few patients have to be tested, thus reducing costs compared to routine VL 
monitoring.
11
 We developed and validated risk charts based on current and past CD4 counts and 
decision rules to guide targeted VL testing.   
Methods 
Data sources 
The International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) is a 
regional collaboration of HIV treatment and care programs, which is part of a consortium of seven 
networks in sub-Saharan Africa, Asia and Pacific, North America, and Caribbean, Central and South 
America.
12–14
 Data are collected at ART initiation and each follow-up visit, using standardized 
AC
CE
PT
ED
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
5 
 
instruments, and transferred in regular intervals to data centers in Switzerland and South Africa. 
Ethical approval was obtained from the ethics committee of the Canton of Bern, Switzerland and the 
University of Cape Town, South Africa. All participating cohorts obtained local ethical committee 
approval to contribute data to this analysis.  
We developed the risk charts using seven South African cohorts: the Gugulethu and Khayelitsha 
township ART programs and Tygerberg hospital in Cape Town,
15–17
 the McCord Hospital in Durban,
18
 
the Helen Joseph Hospital Themba Lethu Clinic and Aurum Institute for Health Research program in 
Johannesburg,
19,20
 and the Hlabisa HIV Treatment and Care program in rural Somkhele, KwaZulu-
Natal.
21
 We describe the seven cohorts, which mainly include urban and township populations, as the 
derivation dataset. We validated the risk charts in the South African Kheth’Impilo cohort, which 
includes health facilities from urban and rural areas in the Eastern Cape, KwaZulu-Natal and 
Mpumalanga,
22
 the Centre for Infectious Diseases and Research in Zambia (CIDRZ), which covers 
urban and periurban populations in Lusaka,
23
 and the TREAT Asia HIV Observational Database 
(TAHOD) in the Asia-Pacific.
24
  
In South Africa all cohorts monitored VL and CD4 cell counts six-monthly. Similarly, from TAHOD we 
included 17 sites in 12 countries that routinely monitored VL and CD4 counts three to six monthly.  In 
CIDRZ monitoring of CD4 cell counts occurs every three to six months and VL is measured in patients 
suspected of failing therapy.  
Inclusion criteria, definitions and imputations of missing values 
We included treatment-naïve patients aged 16 years or older who started first-line ART in 2000 or 
later with a CD4 cell count of 350 cells/µL or lower. Patients needed to have at least one VL 
measurement and one CD4 count 6 months or later after starting ART. The CD4 cell count at the start 
of ART was defined as the measurement closest to the date of starting ART, within a window of 90 
days prior to 30 days after the start of ART. We defined virologic failure as a single VL above 1000 
copies/ml. We included measurements taken up to 5 years after starting ART. In both the derivation 
and validation cohorts we imputed values missing between two measurements by interpolating 
values on the log10 scale for VL and the square root scale for CD4 count. Measurements taken after 
switching to second-line ART were excluded.  
Development of risk charts and rules for targeted VL testing 
We used generalized additive models
25
 with a logit link and thin-plate regression splines
26
 with a 
monotonicity constraint to model the probability of virologic failure and develop the risk charts. In 
model 1 we included the current CD4 count, the CD4 count at start of ART, time on treatment and 
gender. In model 2 the CD4 count at ART initiation was replaced by a count measured 6 months 
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earlier, within a window of 2 and 9 months earlier. Most patients contributed multiple 
measurements during follow-up; these were treated as independent. Models included smoothers for 
the current CD4 count, time on treatment and age. We developed optimal tripartite decision rules to 
support decisions on VL testing in settings where access to VL monitoring is limited, using a method 
developed by Liu et al.
27
 A tripartite decision rule is defined by two cut-off values that classify 
treatment outcomes into three categories, based on the predicted probability of virologic failure: 
successful ART, virologic failure, and uncertain outcome. VL is then measured in patients with 
uncertain outcome. We developed decision rules assuming that resources allow for VL testing of 
10%, 20% or 40% of patients. The cutoffs were then chosen such that the 10%, 20% or 40% of 
patients with the most uncertain outcome are tested. We also determined the optimal cut-off in the 
absence of VL testing. In all rules we gave more weight to avoiding false negatives (60%) than to 
avoiding false positives (40%). In other words we assumed that it is more important to avoid missing 
patients who truly failed than to avoid falsely classifying patients as failing treatment. 
Validation of risk charts and model fit 
We calculated positive predictive values (PPV), negative predictive values (NPV), sensitivity, 
specificity and the area under the receiver-operating curve (AUC) for the derivation and validation 
cohorts. We checked the goodness of fit of the two models by graphically comparing observed and 
predicted risks. We overlaid the plots with a grid of 15x15 cells and compared the proportion of 
failures encountered within each of the 225 cells with the predicted number of failures. Finally, we 
compared the performance of the risk charts with the 2006 and 2013 WHO immunologic criteria for 
treatment failure.
5,9
 The 2006 criteria include a fall of the CD4 count to baseline (or below), a 50% fall 
from the on-treatment peak value and persistent CD4 counts below 100 cells/µl. The 2013 criteria 
are a simplified version of the 2006 criteria that do not include the fall from the on-treatment peak 
value. 
Sensitivity analyses 
We performed three sensitivity analyses. The first was a complete case analysis for which we did not 
impute any missing values. In the second sensitivity analysis we used an alternative imputation 
method where we added random error to interpolated values. Finally, in the third sensitivity analysis 
we examined the impact of assuming that multiple measurements in the same patient are 
independent. We weighted each measurement such that the weights of all measurements of one 
patient added up to 1. Every patient thus contributed the same weight to the analysis. See technical 
appendix, Supplemental Digital Content, http://links.lww.com/QAI/A712 for further details. All 
analyses were done in R 3.0.1 (R Core Team, Vienna, Austria). 
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Results 
Selection of eligible patients 
After excluding patients with missing or ineligible CD4 counts at the start of ART, 31,450 patients 
from the South African derivation cohort,  16,131 patients from the South African, 7,796 patients 
from the Zambian and 1,356 from the Asia Pacific validation cohorts were included in the 
development and validation of the risk charts based on model 1. Numbers were different for the 
second risk chart (model 2), which was based on current and CD4 counts measured 6 months 
previously: 36,511 patients from the derivation cohort in South Africa and 12,909 patients from the 
South African, 2,854 patients from the Zambian and 1,367 patients from the Asia-Pacific validation 
cohorts. The selection of patients with reasons for exclusion is shown in Figure S1, Supplemental 
Digital Content, http://links.lww.com/QAI/A712.  
Patient characteristics 
The 31,450 patients starting ART in one of the seven South African programs had a median age of 36 
years, were predominantly female (18,597; 59%) and started ART with a median CD4 cell count of 
111 cells/µL (Table 1). The characteristics of the patients included in the South African and Zambian 
validation cohorts were similar to the derivation cohort, whereas in the cohorts from Asia-Pacific, 
most patients were men (918; 68%) and the median CD4 cell count at start of ART was lower, 95 
cells/µL. For model 2, patient characteristics were similar (see Table S1, Supplemental Digital 
Content, http://links.lww.com/QAI/A712).  
The development of model 1 was based on 125,590 triplets of laboratory values: the CD4 count 
measured at the start of ART and one CD4 count and VL measured subsequently at the same point in 
time during a total 68,611 person-years of follow-up. The validation datasets were based on 46,997 
triplets measured during 32,005 person-years of follow-up (South Africa), 16,652 triplets measured 
during 19,951 person-years (Zambia) and 8,498 triplets taken during 4,375 person-years (Asia-
Pacific). In the derivation cohorts 11,972 (10%) of VL values and 12,045 (10%) of CD4 counts had 
been imputed by interpolation. Compared to the derivation cohorts the proportion of imputed 
values was greater in the validation cohorts from South Africa and Zambia, and greater for VL in Asia-
Pacific (Table 1). The numbers were similar for model 2 (see Table S1, Supplemental Digital Content, 
http://links.lww.com/QAI/A712). 
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Risk charts 
The risk chart for virologic failure based on model 1 is shown in Figure 1, stratified by CD4 count at 
the start of ART and gender. Low probabilities of virologic failures are shown in blue, intermediate 
probabilities in yellow and orange, and high probabilities in red. At a given combination of current 
and CD4 count at the start of ART, the probability of virologic failure increases with time on ART, and 
is somewhat lower in women than in men. The optimal probability area where patients should be 
tested if resources allow the testing of 10%, 20% or 40% of patients are also shown. The range of 
patients to be tested widens with duration on ART, reflecting increasing uncertainty. Figure 2 shows 
the risk chart for model 2, stratified by CD4 count measured 6 months previously and gender. Again, 
at a given combination of current and previous CD4 count, the probability of virologic failure 
increases with time on ART, and is lower in women than in men. Alternative presentations of the two 
risk charts are given in Figure S2 and Figure S3, Supplemental Digital Content, 
http://links.lww.com/QAI/A712. 
Accuracy of charts and targeted VL testing 
The range of probabilities resulting in the testing of 10%, 20% and 40% of patients in the derivation 
cohort slightly differed between models. E.g., when assuming that 20% of patients can be tested this 
range was 0.22 to 0.64 for model 1 and 0.20 to 0.67 for model 2. With model 1 the PPV increased 
from 61% to 87%, 94% and 98% in the South African derivation cohort when moving from no VL 
testing to the testing of 10%, 20% and 40% of patients (Table 2). The PPVs for the South African 
validation cohort increased from 48% (no testing) to 79% (10% tested), 91% (20% tested) and 98% 
(40% tested). The corresponding PPVs for Zambia were 35%, 64%, 80% and 93%, and for Asia-Pacific 
37%, 73%, 88% and 96%. NPVs were close to 90% in all cohorts even without targeted VL testing, and 
generally above 90% with targeted testing, except for the South African validation cohort with no 
testing (81%) and testing of 10% and 20% of patients (84%; 87%). Sensitivities increased from 33% 
(no VL testing) to 74% (40% tested) in the derivation cohort and, in the validation cohorts, from 24% 
(no VL testing) to 68% (40% tested) in South Africa, from 43% to 82% in Zambia and from 25% to 71% 
in the Asia-Pacific cohorts (Table 2). The AUCs ranged from 0.63 using model 2 in the Zambian 
validation cohort without targeted VL testing to 0.95 in the South African derivation cohorts when 
using model 1 and assuming that 40% of patients had VL tests (Figure 3).  
Table S2, Supplemental Digital Content, http://links.lww.com/QAI/A712 gives PPVs, NPVs, sensitivity 
and specificity for different threshold probabilities for virologic failure, assuming that targeted VL 
testing is not available. As expected, the PPV increased with higher thresholds whereas sensitivity 
declined. The comparison with the WHO criteria for immunological failure showed that in the 
absence of targeted VL monitoring the performance of the risk charts and the different WHO criteria 
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was similar (see Table S3, Supplemental Digital Content, http://links.lww.com/QAI/A712). The 
goodness of fit of the two models, as assessed by comparing observed and predicted risks, was 
generally high (see technical appendix, Supplemental Digital Content, 
http://links.lww.com/QAI/A712 for details).   
Sensitivity analyses 
The results of the complete case analysis were similar to the main analysis, with only small 
differences in the accuracy of predictions, typically in the range of plus or minus 0% to 5% in PPV, 
NPV, sensitivity or specificity (see Table S4, Supplemental Digital Content, 
http://links.lww.com/QAI/A712). The same was the case when adding random normal errors to the 
imputed values used in the main analysis (see Table S5, Supplemental Digital Content, 
http://links.lww.com/QAI/A712). Finally, the results of the analysis to which each patient contributed 
the same weight were also similar to the main analysis (see Table S6, Supplemental Digital Content, 
http://links.lww.com/QAI/A712).  
 
Discussion 
 
The measurement of the CD4 count remains necessary to assess ART eligibility in many settings, and 
the CD4 count is also important to gauge the risk of clinical progression and guide clinical decisions 
about prophylactic treatments and screening for opportunistic infections.
9,10
 We used data from the 
large IeDEA collaboration to develop and validate charts of the risk of virologic failure in adult HIV-
positive patients starting ART, based on two CD4 counts measured at different points in time. Over 
30,000 adult patients starting ART were involved in the development of the charts, and up to 25,000 
patients were included in their validation. The risk charts define optimal ranges of risk at which 
patients should be tested for VL, assuming that resources permitted the targeted testing of 10%, 
20%, or 40% of patients. The PPVs increased substantially with targeted VL testing, even when only 
10% of patients were tested, and was around 90% with the testing of 20% of patients. Sensitivity also 
increased: the decision rule based on the testing of 20% of patients identified 50% to 70% of patients 
with virologic failure.  
The development of the charts based on seven South African urban and townships cohorts, the 
definition of tripartite decision rules using state-of-the-art methods,
27
 and the thorough validation 
are important strengths of this study. The risk charts were validated in a large ART program in the 
Eastern Cape, KwaZulu-Natal and Mpumalanga provinces of South Africa, which included many rural 
treatment sites, a treatment program in the greater Lusaka metropolitan area in Zambia, and 
programs in 12 different countries in the Asia-Pacific region. Our study therefore meets several 
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dimensions of generalizability and applicability, including geographic, spectrum and methodological 
transportability.
28
 Indeed, accuracy was maintained when the charts were tested in patients from 
different locations, with more or less advanced immunodeficiency, and across sites that differed with 
respect to data collection, follow-up intervals and monitoring strategies. Such multiple validations 
are possible only in large international cohort collaborations such as IeDEA.
12
 
VL testing to monitor ART is strongly recommended by WHO.
9,10
 However, a 2012 survey found that 
few programs in Sub-Saharan Africa had access to routine VL testing.
29
 As discussed in detail in recent 
WHO and UNITAID reports,
10,30
 scaling up VL testing in resource limited settings is challenging. For 
example, plasma obtained from EDTA coagulated whole blood is the preferred sample for the 
common VL platforms, but obtaining plasma may not be feasible in remote clinics, due to the lack of 
electricity to operate centrifuges and maintain the cold-chain.
10
 Point-of-care laboratory tests are 
being developed both for CD4 cell count and VL.
31
 Some point-of-care VL tests are designed to be 
used in clinics in remote settings, by auxiliary staff and in the absence of a reliable electricity supply. 
The risk charts may facilitate the cost-effective use of point-of-care and standard VL tests,
32
 and 
generally support the transition to routine VL monitoring.
10
  
As in previous studies
33–35
 we defined virologic failure as a single VL above 1000 copies/ml. Virologic 
failure should not be confused with treatment failure, which is defined by WHO as two consecutive 
VL measurements exceeding 1000 copies/ml, within a three-month interval, with adherence support 
between measurements, after at least six months of using ARV drugs.
9
 Also, we stress that the risk 
charts inform decisions on VL testing and adherence support but they do not on their own provide 
conclusive evidence for switching patients to second-line ART. Furthermore, although our study 
assessed the accuracy of the risk charts in different patient populations, it did not examine the 
effects of using these charts to monitor patients starting ART in resource-limited settings. Ideally, 
different monitoring strategies should be compared in pragmatic randomized trials with patient-
relevant outcomes such as disease progression and mortality. Previous trials compared clinical 
monitoring with routine CD4 count monitoring, or CD4 count with CD4 count and VL monitoring.
36,37
 
To our knowledge no trials of risk-based targeted VL monitoring have been done.   
The models underlying the charts might be improved by including other variables predictive of 
virologic failure. The lack of data on adherence is an important limitation of our study: in the Aid for 
AIDS program in Southern Africa adherence assessments based on pharmacy refill data were as 
accurate as CD4 counts for detecting virologic failure.
38
 A clinical prediction rule developed at the 
Sihanouk Hospital Center of Hope in Cambodia (based on adherence, and changes in CD4 cell count 
and hemoglobin values) had a sensitivity close to 50% and specificity of over 90%.
33
 The performance 
of other scoring systems was similar, with improved sensitivity compared to the WHO criteria.
34,35
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Few of these scores had undergone external validation, but it is noteworthy that the sensitivity of the 
Cambodian score dropped to 23% when used in Uganda.
34
  
Our study has other limitations. We only considered patients starting ART at CD4 cell counts of 350 
cells/µL or below. Some countries are moving towards initiating patients at a CD4 count below 500 
cells/µL and initiate ART in all pregnant women regardless of CD4. However, most patients still 
initiate ART at much lower CD4 counts. For example, in 2013, the median CD4 cell count was  
231 cells/µL in the Republic of South Africa, 212 cells/µL in Malawi, 205 cells/µL in Botswana and 180 
cells/µL in Tanzania.
39
 The charts will therefore be relevant to many adult patients, and a similar 
study in children is now under way. Also, the charts will be updated and extended to beyond 5 years 
as more data accumulate in the IeDEA cohorts.  
In conclusion, the risk charts developed and validated in this study should be useful for a range of 
ART programs and settings, including programs that have relied on CD4 count monitoring and are 
now transitioning to targeted or routine VL testing. In settings that continue to have no access to VL 
testing the charts may provide a more user-friendly alternative to the WHO immunologic criteria for 
treatment failure.
5,9
 Field studies are now required to clarify the utility of these charts.  
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Figure 1. Risk chart for virologic failure based on time on antiretroviral therapy and 
current CD4 cell count stratified by baseline CD4 (columns) and gender (rows). The area 
between two lines of the same style contains the patients that are optimally tested given 
the resources available. 
 
Figure 2. Risk chart for virologic failure based on time on antiretroviral therapy and 
current CD4 cell count stratified by CD4 count measured 6 months previously (columns) 
and gender (rows). The area between two lines of the same style contains the patients 
that are optimally tested given the resources available.   
 
Figure 3. Receiver Operator Curves for Model 1 (upper panels) and Model 2 (lower 
panels) for the derivation and validation datasets (columns). The curves were computed 
assuming that no patients, 10%, 20% or 40% of patients were tested for viral load. The 
numbers indicate the area under the curve (AUC) value of the corresponding curves. 
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Table 1. Baseline characteristics of patients included in the development and validation 
of risk charts for virologic failure on antiretroviral therapy based on current and baseline 
CD4 count.  
    
South Africa 
(derivation) 
South Africa 
(validation) 
Zambia 
(validation) 
Asia-Pacific 
(validation) 
Patients     
 Number of patients 31,450 (100%) 16,131 (100%) 7,796 (100%) 1,356 (100%) 
 Gender     
 Female 18,597 (59%) 11,143 (69%) 4,237 (54%) 438 (32%) 
 Male 12,853 (41%)  4,988 (31%) 3,559 (46%) 918 (68%) 
 Age (years)     
 Median (IQR) 36 (30 – 42) 35 (30 – 42) 36 (31 – 43) 35 (31 – 43) 
 16 - 29  6,728 (21%) 3,751 (23%) 1,370 (18%) 279 (21%) 
 30 - 39 13,899 (44%) 7,241 (45%) 3,599 (46%) 615 (45%) 
 40 - 49  7,705 (24%) 3,725 (23%) 2,021 (26%) 324 (24%) 
 >= 50  3,118 (10%) 1,414 (9%)   806 (10%) 138 (10%) 
 CD4 count at start of ART (cells/μl)     
 Median (IQR) 111 (50 – 174) 129 (72 – 174) 114 (58 – 180) 95 (31 – 184) 
 < 50  7,800 (25%) 2,611 (16%) 1,621 (21%) 463 (34%) 
 50 - 99  6,465 (21%) 3,321 (21%) 1,788 (23%) 226 (17%) 
 100 - 199 12,581 (40%) 8,400 (52%) 2,973 (38%) 375 (28%) 
 200 - 349  4,593 (15%) 1,792 (11%) 1,409 (18%) 292 (22%) 
 Year of starting ART     
 Median (IQR) 2006 (2005 – 2007) 2008 (2007 – 2009) 2006 (2005 – 2007) 2004 (2002 – 2005) 
 Follow up time (years)     
 Median (IQR) 1.92 (1.09 – 3.04) 1.72 (1.06 – 2.70) 2.50 (1.64 – 3.32) 3.39 (2.03 – 4.58) 
 Total 68,611 32,005 19,951 4,375 
      
Laboratory values     
 No. of triplets analysed* 125,590 (100%) 46,997 (100%) 16,652 (100%) 8,498 (100%) 
 No. with virologic failure 20,879 (17%) 10,642 (23%) 2,904 (17%) 828 (11%) 
      
 No. of imputed CD4 counts 12,045 (10%) 14,355 (31%) 5,980 (36%) 532 (6%) 
  No. of imputed VL measurements 11,972 (10%) 14,468 (31%) 4,815 (29%) 3,214 (38%) 
*: Baseline CD4 count and CD4 count and VL measured at the same time during follow-up. 
VL, viral load 
 
 
 
 
Table 2. Accuracy of prediction of virologic failure in derivation and validation cohorts. Results are 
shown for no viral load testing and for the testing of 20% or 40% of patients, using optimal rules for 
the range of patients tested based on the predicted probability of virologic failure.  
 
    Current and baseline CD4 count  Current CD4 count and CD4 count measured 3 
months previously  
 (Model 1) (Model 2) 
  South 
Africa 
(derivation) 
South 
Africa 
(validation) 
Zambia 
(validation) 
Asia-
Pacific 
(validation) 
South 
Africa 
(derivation) 
South 
Africa 
(validation) 
Zambia 
(validation) 
Asia-
Pacific 
(validation) 
  0% viral load testing 
 Probability cut off: 0.38 Probability cut off: 0.36 
PPV 61% 48% 35% 37% 56% 49% 28% 29% 
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NPV 88% 81% 87% 91% 88% 79% 89% 92% 
Sensitivity 33% 24% 43% 25% 24% 19% 29% 18% 
Specificity 96% 92% 83% 95% 97% 94% 89% 95% 
  10% viral load testing 
 Probability range tested: 0.29 - 0.55 Probability range tested: 0.26 - 0.56 
PPV 87% 79% 64% 73% 89% 82% 71% 78% 
NPV 90% 84% 91% 93% 90% 82% 92% 93% 
Sensitivity 44% 35% 55% 37% 36% 30% 43% 29% 
Specificity 99% 97% 93% 98% 99% 98% 97% 99% 
% tested 10% 14% 22% 12% 10% 13% 22% 12% 
  20% viral load testing 
 Probability range tested: 0.22 - 0.64 Probability range tested: 0.2 - 0.67 
PPV 94% 91% 80% 88% 96% 93% 88% 93% 
NPV 92% 87% 93% 94% 92% 84% 94% 94% 
Sensitivity 56% 49% 68% 49% 50% 42% 56% 41% 
Specificity 99% 99% 96% 99% 100% 99% 99% 100% 
% tested 20% 26% 40% 24% 20% 24% 39% 24% 
  40% viral load testing 
 Probability range tested: 0.14 - 0.76 Probability range tested: 0.13 - 0.94 
PPV 98% 98% 93% 96% 100% 100% 100% 100% 
NPV 95% 92% 96% 97% 95% 89% 96% 96% 
Sensitivity 74% 68% 82% 71% 69% 62% 73% 63% 
Specificity 100% 100% 99% 100% 100% 100% 100% 100% 
% tested 40% 49% 65% 45% 40% 45% 62% 44% 
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Figure 1. Risk chart for virologic failure based on time on antiretroviral therapy and 
current CD4 cell count stratified by baseline CD4 (columns) and gender (rows). The area 
between two lines of the same style contains the patients that are optimally tested given 
the resources available. 
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Figure 2. Risk chart for virologic failure based on time on antiretroviral therapy and 
current CD4 cell count stratified by CD4 count measured 6 months previously (columns) 
and gender (rows). The area between two lines of the same style contains the patients 
that are optimally tested given the resources available.   
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Figure 3. Receiver Operator Curves for Model 1 (upper panels) and Model 2 (lower 
panels) for the derivation and validation datasets (columns). The curves were computed 
assuming that no patients, 10%, 20% or 40% of patients were tested for viral load. The 
numbers indicate the area under the curve (AUC) value of the corresponding curves. 
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